Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Mite Trial Failure 'The Final Straw' As Circassia Ends Anti-Allergy Investing

Executive Summary

Circassia has thrown in the towel on investing in anti-allergy vaccines and will focus now on respiratory activities, after its house dust mite allergy study missed its primary endpoints.

Advertisement

Related Content

Circassia Builds US Respiratory Presence with AstraZeneca Deal
Turmoil In Allergy Market Continues As Merck Ends ALK Partnership
Circassia paying £188m for two asthma firms, but it's still an allergy specialist
Circassia puts money where mouth is; IPO floats at top price

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel